Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

NCT ID: NCT02909972

Last Updated: 2019-11-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 55 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-09-30
• Study Completion Date: 2019-08-31

Brief Summary

Phase 1/1b, open label, multi-center dose escalation and dose expansion study designed to evaluate safety, tolerability, PK (pharmacokinetics), PD (pharmacodynamics) and anti-tumor effects of ALRN-6924 alone or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia or advanced myelodysplastic syndrome with wild-type (WT) TP53

Detailed Description

Phase I, open label, multi-center dose escalation (DEP) and dose expansion (EXP) study designed to evaluate safety, tolerability, PK (pharmacokinetics), PD (pharmacodynamics) and anti-tumor effects of ALRN-6924 in patients with acute myeloid leukemia or advanced myelodysplastic syndrome with wild-type (WT) TP53. ALRN-6924 is a stabilized cell-permeating peptide designed to disrupt interaction between the p53 tumor suppression protein and its endogenous inhibitors murine double minute 2 (MDM2) and murine double minute X (MDMX)

Men and women 18 years of age and older with relapsed or refractory acute myeloid leukemia or advanced myelodysplastic syndrome and for which standard treatment(s) are not available or are no longer effective can be enrolled. Treatment of patients in the DEP and EXP phases will continue in the study until documentation of disease progression, unacceptable toxicity, or patient or physician decision to discontinue study participation is made.

Conditions

Acute Myeloid Leukemia; Myelodysplastic Syndromes

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ALRN-6924

Fixed dose of ALRN-6924 per cohort, administered IV, Days 1, 8, and 15 every 28 days

Group Type: EXPERIMENTAL

ALRN-6924

Intervention Type: DRUG

Fixed dose of ALRN-6924 per cohort, administered IV, Days 1, 8, and 15 every 28 days.

ALRN-6924 in combination with cytarabine

Cytarabine (100 or 200 mg/m2) will be administered as an IV infusion followed by ALRN-6924 on Days 1, 8, and 15 every 28 days.

Group Type: EXPERIMENTAL

ALRN-6924 in combination with cytarabine

Intervention Type: DRUG

Cytarabine (100 or 200 mg/m2) will be administered as an IV infusion followed by ALRN-6924 on Days 1, 8, and 15 every 28 days.

Interventions

ALRN-6924

Fixed dose of ALRN-6924 per cohort, administered IV, Days 1, 8, and 15 every 28 days.

Intervention Type: DRUG

ALRN-6924 in combination with cytarabine

Cytarabine (100 or 200 mg/m2) will be administered as an IV infusion followed by ALRN-6924 on Days 1, 8, and 15 every 28 days.

Intervention Type: DRUG

Other Intervention Names

ALRN-6924 in combination with Ara-C

Eligibility Criteria

Inclusion Criteria

• Relapsed or refractory acute myeloid leukemia or IPSS-R intermediate/high/very high-risk MDS patients
• Confirmed or anticipated wild-type TP53
• ECOG (Eastern Cooperative Oncology Group) performance status 0-2
• Adequate hepatic and renal function
• Acceptable coagulation function
• Negative serum or urine pregnancy test within 7 days prior to the first dose of ALRN-6924 for women of child-bearing potential
• Sufficient wash out from prior therapies and recovery from all significant toxicities

Exclusion Criteria

• Patients are eligible for available approved standard therapies
• Prior treatment with MDM2 inhibitor, with protocol specified exceptions
• Patients with history of allogeneic stem cell transplantation
• Leukemic blast counts of >25,000/µl
• Deletion of chromosome 17, or del(17p)
• Patients with evidence of current central nervous system leukemic involvement
• Known hypersensitivity to any study drug component
• History of coagulopathy
• Prior specified cardiovascular risk factors
• Clinically significant gastrointestinal bleeding within 6 months
• Clinically significant third-space fluid accumulation
• Pregnant or lactating females
• Evidence of any serious and/or unstable pre-existing medical condition that would interfere with patient safety ability to provide informed consent
• Active uncontrolled infection, including HIV/AIDS or Hepatitis B or C
• Second malignancy within one year, with protocol specified exceptions

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Aileron Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Denver, Colorado, United States

Tampa, Florida, United States

The Bronx, New York, United States

Portland, Oregon, United States

Greenville, South Carolina, United States

Nashville, Tennessee, United States

Countries

United States

Other Identifiers

ALRN-6924-1-02

Identifier Type: -

Identifier Source: org_study_id